GlassScriptPhysician profile
Destonee R Wilson
NPI 1174041578
$4,995.78
in general payments reported to CMS, 2019-2025
39 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,038 · 2023: $1,586 · 2024: $1,325 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,957.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $651.17 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $537.70 | 2022-2025 | |
| Abbott Laboratories | $418.36 | 2022-2024 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.03 | 2022-2024 | Jardiance |
| Pfizer INC. | $329.94 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.77 | 2022-2025 | Cycloset, Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $156.99 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $155.25 | 2022-2025 | |
| Amgen INC. | $139.04 | 2022-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $131.70 | 2022-2025 | Airsupra, Farxiga, Fasenra |
| Biohaven Pharmaceutical Holding Company LTD. | $130.49 | 2022 | |
| Corium, LLC | $116.57 | 2023-2024 | Azstarys |
| Exact Sciences Corporation | $76.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $75.46 | 2023 | Quviviq |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $73.78 | 2022-2024 | Livalo, Seglentis |
| Sanofi Pasteur INC. | $66.69 | 2023-2024 | |
| Depuy Synthes Sales INC. | $60.27 | 2023-2024 | Monovisc |
| Amarin Pharma, INC. | $53.42 | 2022 | |
| Alk-Abello, INC | $52.12 | 2025 | Grastek, Ragwitek, Odactra |
| Axsome Therapeutics, INC. | $49.41 | 2024-2025 | Auvelity, Symbravo |
| Xeris Pharmaceuticals, INC. | $41.63 | 2025 | Keveyis |
| Halozyme INC | $37.51 | 2023 | |
| Ibsa Pharma INC. | $36.15 | 2022-2024 | Licart, Tirosint |
| Otsuka America Pharmaceutical, INC. | $35.90 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $33.39 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $31.17 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $31.05 | 2024-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Organon LLC | $19.76 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.89 | 2024 | Voquezna |
| Acella Pharmaceuticals, LLC | $18.47 | 2024 | NP Thyroid 60 |
| Si-Bone, INC. | $17.83 | 2025 | |
| Philips North America LLC | $16.22 | 2024 | (Ck7) Extended Holter |
| Astellas Pharma US INC | $15.44 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $15.26 | 2022 | |
| Shield Therapeutics INC | $14.63 | 2024 | |
| Smith+Nephew, INC. | $13.81 | 2025 | Collagenase Santyl |
| Seqirus USA INC | $12.80 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destonee Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.